356 related articles for article (PubMed ID: 3016500)
1. Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis.
Jard S; Gaillard RC; Guillon G; Marie J; Schoenenberg P; Muller AF; Manning M; Sawyer WH
Mol Pharmacol; 1986 Aug; 30(2):171-7. PubMed ID: 3016500
[TBL] [Abstract][Full Text] [Related]
2. Iodination of vasopressin analogues with agonistic and antagonistic properties: effects on biological properties and affinity for vascular and renal vasopressin receptors.
Jard S; Lombard C; Seyer R; Aumelas A; Manning M; Sawyer WH
Mol Pharmacol; 1987 Sep; 32(3):369-75. PubMed ID: 2959851
[TBL] [Abstract][Full Text] [Related]
3. Interaction of rat adenohypophyseal vasopressin receptors with vasopressin analogues substituted at positions 7 and 1: dissimilarity from the V1 vasopressin receptor.
Knepel W; Götz D; Fahrenholz F
Neuroendocrinology; 1986; 44(3):390-6. PubMed ID: 3027602
[TBL] [Abstract][Full Text] [Related]
4. WRK1 cells: a model system for studying properties of V1a vasopressin receptors.
Jard S; Guillon G; Balestre MN; Kirk C
J Cardiovasc Pharmacol; 1986; 8 Suppl 7():S12-7. PubMed ID: 2434765
[TBL] [Abstract][Full Text] [Related]
5. Vascular vasopressin receptors mediate inhibition of beta adrenergic receptor-induced cyclic AMP accumulation.
Nambi P; Whitman M; Stassen FL; Crooke ST
J Pharmacol Exp Ther; 1986 Apr; 237(1):143-6. PubMed ID: 3007735
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of arginine vasopressin receptors in the rat testis.
Meidan R; Hsueh AJ
Endocrinology; 1985 Jan; 116(1):416-23. PubMed ID: 2981073
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of renal adenylate cyclase-coupled vasopressin receptors after chronic administration of vasopressin antagonists to rats.
Caltabiano S; Kinter LB
J Pharmacol Exp Ther; 1991 Sep; 258(3):1046-54. PubMed ID: 1832462
[TBL] [Abstract][Full Text] [Related]
8. [Vasopressin isoreceptors in the liver and kidney: relationship between hormone binding and biological response].
Jard S
J Physiol (Paris); 1981; 77(4-5):621-8. PubMed ID: 6268774
[TBL] [Abstract][Full Text] [Related]
9. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
[TBL] [Abstract][Full Text] [Related]
10. A novel type of vasopressin receptor on anterior pituitary corticotrophs?
Baertschi AJ; Friedli M
Endocrinology; 1985 Feb; 116(2):499-502. PubMed ID: 2981663
[TBL] [Abstract][Full Text] [Related]
11. The development of vasopressin antagonists.
Sawyer WH; Manning M
Fed Proc; 1984 Jan; 43(1):87-90. PubMed ID: 6317468
[TBL] [Abstract][Full Text] [Related]
12. Design of oxytocin antagonists, which are more selective than atosiban.
Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
[TBL] [Abstract][Full Text] [Related]
13. C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors.
Manning M; Misicka A; Olma A; Klis WA; Bankowski K; Nawrocka E; Kruszynski M; Kolodziejczyk A; Cheng LL; Seto J
J Med Chem; 1987 Dec; 30(12):2245-52. PubMed ID: 2960812
[TBL] [Abstract][Full Text] [Related]
14. Molecular cloning and expression of a rat V1a arginine vasopressin receptor.
Morel A; O'Carroll AM; Brownstein MJ; Lolait SJ
Nature; 1992 Apr; 356(6369):523-6. PubMed ID: 1560825
[TBL] [Abstract][Full Text] [Related]
15. Natriuretic action of neurohypophysial peptides: effects of agonists and antagonists and implication of natriuretic receptor.
Chan WY; Hruby VJ
J Pharmacol Exp Ther; 1988 Aug; 246(2):597-602. PubMed ID: 2969979
[TBL] [Abstract][Full Text] [Related]
16. [Regulation of V1-vasopressinergic receptors in the rat].
Thibonnier M; Snajdar R; Rapp J
Arch Mal Coeur Vaiss; 1986 Jun; 79(6):824-7. PubMed ID: 3026272
[TBL] [Abstract][Full Text] [Related]
17. [1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors.
Derick S; Cheng LL; Voirol MJ; Stoev S; Giacomini M; Wo NC; Szeto HH; Ben Mimoun M; Andres M; Gaillard RC; Guillon G; Manning M
Endocrinology; 2002 Dec; 143(12):4655-64. PubMed ID: 12446593
[TBL] [Abstract][Full Text] [Related]
18. Arginine-vasopressin analogues with high antidiuretic/vasopressor selectivity. Synthesis, biological activity, and receptor binding affinity of arginine-vasopressin analogues with substitutions in positions 1, 2, 4, 7, and 8.
Grzonka Z; Kasprzykowski F; Kojro E; Darlak K; Melin P; Fahrenholz F; Crause P; Boer R
J Med Chem; 1986 Jan; 29(1):96-9. PubMed ID: 2416923
[TBL] [Abstract][Full Text] [Related]
19. Studies of the nature of the interaction between vasopressin and corticotropin-releasing factor on adrenocorticotropin release in the rat.
Rivier C; Rivier J; Mormede P; Vale W
Endocrinology; 1984 Sep; 115(3):882-6. PubMed ID: 6086290
[TBL] [Abstract][Full Text] [Related]
20. Effects of arginine-8-vasopressin and 1-deamino-8-D-arginine-vasopressin on ACTH secretion in rats.
László FA; Janáky T; Julesz J; Kárteszi M; Makara GB; Stark E
Endocrinol Exp; 1983 Jun; 17(2):133-6. PubMed ID: 6309504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
